Scancell Holdings (GB:SCLP) has released an update.
Scancell Holdings, a developer of cancer immunotherapies, has been bolstered by expert endorsement for its upcoming Phase 2/3 SCOPE-2 trial in melanoma treatment. The trial, featuring an early interim analysis of Overall Response Rate, aims to culminate in a pivotal progression-free survival analysis. This follows encouraging feedback from the ASCO presentation and the continued recruitment for the ongoing SCOPE study, with key clinical results expected in late 2024 and early 2025.
For further insights into GB:SCLP stock, check out TipRanks’ Stock Analysis page.
